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Nuclear Factor κB Inhibitors Alleviate 
and the Proteasome Inhibitor PS-341 
Exacerbates Radiation Toxicity 
in Zebrafish Embryos
Abstract
Inflammatory changes are a major component of the normal tissue response to ionizing radiation, 
and increased nuclear factor κB (NF-κB) activity is an important mediator of inflammatory responses. 
Here, we used zebrafish embryos to assess the capacity of two different classes of pharmacologic agents 
known to target NF-κB to modify radiation toxicity in the vertebrate organism. These were proteasome 
inhibitors, including lactacystin, MG132, and PS-341 (Bortezomib/VELCADE), and direct inhibitors of 
NF-κB activity, including ethyl pyruvate (EP) and the synthetic triterpenoid CDDO-TFEA (RTA401), 
among others. The proteasome inhibitors either did not significantly affect radiation sensitivity of 
zebrafish embryos (MG132, lactacystin) or rendered zebrafish embryos more sensitive to the lethal 
effects of ionizing radiation (PS-341). Radiosensitization by PS-341 was reduced in fish with impaired 
p53 expression or function but not associated with enhanced expression of select p53 target genes. In 
contrast, the direct NF-κB inhibitors EP and CDDO-TFEA significantly improved overall survival of 
lethally irradiated zebrafish embryos. In addition, direct NF-κB inhibition reduced radiation-induced 
apoptosis in the central nervous system, abrogated aberrations in body axis development, restored 
metabolization and secretion of a reporter lipid through the gastrointestinal system, and improved renal
clearance compromised by radiation. In contrast to amifostine, EP and CDDO-TFEA not only protected 
against but also mitigated radiation toxicity when given 1 to 2 hours postexposure. Finally, four 
additional IκB kinase inhibitors with distinct mechanisms of action similarly improved overall survival of 
lethally irradiated zebrafish embryos. In conclusion, inhibitors of canonical pathways to NF-κB activation 
may be useful in alleviating radiation toxicity in patients. [Mol Cancer Ther 2009;8(9):2625-34]
Introduction
Normal tissue damage limits the dose of ionizing radiation that can be safely administered to 
treat neoplastic disease. A well-known example of this problem is inflammation of the oral 
mucosa and of the lining of the gastrointestinal tract in tumor patients receiving chemotherapy or 
radiation.1 Depending on the area of the body treated with radiation, other organ sites including 
the lungs and the pericardium also manifest radiation-induced inflammation. A pervasive 
feature of ionizing radiation–associated inflammation is the increased presence of proinflammatory 
cytokines including tumor necrosis factor-α (TNF-α) and interleukin-6, both locally and in 
the circulation.2 In contrast to intracellular regulators of the DNA damage response, these 
and other inflammatory mediators act in a paracrine fashion affecting diverse cell types in the 
tissue microenvironment or even at a distance.3 This circumstance highlights the necessity to 
use animal models to investigate the relative contribution of inflammatory changes to the 
overall response to radiation-induced cell and tissue injury in a multicellular organism. 
In recognition of this need, we recently 
established zebrafish embryos as a facile 
vertebrate in vivo system to monitor the effects 
of radiation protectors on normal tissues
during development.4
The nuclear factor κB (NF-κB) family of 
transcription factors represents a diverse and 
shared signaling mechanism activated during 
cell stress responses.5 In addition, deregulated 
NF-κB signaling has been implicated in the 
malignant phenotype and treatment resistance 
of select tumor forms.6-10 The canonical pathway 
to NF-κB activation leads to IκB kinase 
β (IKKβ)-dependent phosphorylation and 
subsequent proteasomal degradation of the
NF-κB inhibitor IκB, increased nuclear presence 
of NF-κB dimers, and enhanced NF-κB–
dependent transcriptional activity.5 
Whole-body radioprotection through anti-
inflammatory agents has very recently been 
shown in animal models. Specifically, certain 
triterpenoids (CDDO and derivatives thereof) 
have been shown to selectively protect normal 
mouse tissues against the deleterious effects of 
ionizing radiation.11 Furthermore, ethyl pyruvate 
(EP), a derivative of the end product of 
glycolysis, similarly protects normal cells against 
the deleterious effects of radiation both in vitro 
and in mice.12 Among other molecular targets, 
both drugs inhibit activation of NF-κB. 
EP inhibits NF-κB signaling through direct 
molecular interaction with a reactive cysteine of 
the p65 subunit of NF-κB13 whereas CDDO-
TFEA binds to a reactive cysteine (Cys179) of 
IKKα, thus inhibiting its kinase activity.14 
However, these drugs also target other signaling 
molecules and pathways of potential relevance 
to the radiation response, including signal 
transducers and activators of transcription 
3 and Jaks.15, 16 In addition to these agents 
proteasome inhibitors have been shown to
inhibit NF-κB–dependent transcription, and 
one of these (PS-341; Bortezomib; VELCADE) 
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has been Food and Drug Administration–approved for clinical use 
in patients afflicted with multiple myeloma (for review see refs.17, 18). 
It is presently unknown whether and how proteasome inhibitors affect 
whole-body radiation sensitivity.
Collectively, these results raised the question whether inhibition of 
NF-κB activity by different pharmacologic agents contributes to the 
protection of normal cells and tissues against damage induced by ionizing 
radiation. Here, we addressed this issue using zebrafish embryos as an 
in vivo model system. We observed that the NF-κB inhibitors EP and 
CDDO-TFEA afforded protection to zebrafish embryos against the 
lethal effects of radiation in the pre-exposure and postexposure settings, 
i.e., when administered hours after radiation exposure. Radiation 
protection extended to multiple organ sites including the gastrointestinal 
system and, importantly, was also observed when using additional IKK 
inhibitors with different modes of action. In contrast, several proteasome 
inhibitors, including PS-341, did not protect against, but rather moderately 
exacerbated radiation-associated normal tissue toxicity in zebrafish 
embryos. These results predict a favorable therapeutic index for the use 
of inhibitors of canonical pathways to NF-κB activation in combination 
with radiation therapy.
Materials and Methods
Embryo Harvesting and Maintenance
Zebrafish were mated in embryo collection tanks. Viable embryos were 
washed and sorted (25 embryos per 60-mm dish) at the one- to two-
cell developmental stage, and maintained under normoxic conditions at 
28.5°C to enable normal development. Embryo medium was changed at 
24, 72, and 120 h postfertilization (hpf). All procedures using live zebrafish 
were approved by the Institutional Animal Care and Use Committee at 
Thomas Jefferson University. In select experiments, embryos (24 hpf) 
were dechorionated by placement in embryo medium supplemented 
with 50 μg/mL pronase (Sigma) for approximately 10 min at room 
temperature, then gently agitated with a plastic pipette until the embryos 
were liberated from the disrupted chorions. After dechorionation, the 
embryos were rinsed thoroughly with embryo medium, and placed 
in fresh embryo medium.
Radiation Exposure and Drug Treatments
Pharmacological agents [EP was kindly provided by CDDO-TFEA 
was from Reata Pharmaceuticals; IKK inhibitor 2 (Weldelolactone), 
IKK inhibitor 3 (BMS-345541), IKK-2 inhibitor 4, and IKK-2 inhibitor 
5 (IMD-0354) were from Calbiochem; MG132 was from Sigma; PS-341 
was from Millennium Pharmaceuticals; and lactacystin was from 
Calbiochem) were dissolved in embryo medium containing <0.1% DMSO. 
Embryo medium was used as a vehicle control in all experiments. Unless 
stated otherwise embryos were exposed to ionizing radiation ranging in 
dose from 0 to 20 Gy at 24 hpf using an X-ray machine (Gulmay Medical) 
or a 137Cs radiation source. Toxicity analyses for EP (<10 mmol/L), 
CDDO-TFEA (<10 μmol/L), PS-341 (<10 μmol/L), MG132 (<50 
μmol/L), or lactacystin (<10 μmol/L) were conducted by monitoring 
survival and development of zebrafish embryos for 7 d in the absence of 
radiation. To determine modulation of radiation-induced toxicity, EP 
(1 mmol/L) or CDDO-TFEA (1 μmol/L) was added to embryos either 
1 h before or up to 3 h after radiation exposure at 24 hpf. The proteasome 
inhibitors were added to zebrafish embryos 1 h prior to ionizing radiation. 
After irradiation, zebrafish embryos were maintained at 28.5°C for up 
to 7 d postfertilization to monitor effects of treatments on survival,
morphology, and organ-specific toxicity.
Analysis of Treatment Effects on Zebrafish Survival and 
Gross Morphology
Dechorionated embryos at 72 hpf were anesthetized with a 1:100 dilution of 
4 mg/mL tricaine methanesulfonate (Sigma) and immobilized by placing 
them on 3% methylcellulose on a glass depression slide. Morphology 
was assessed visually using a light transmission microscope (Olympus 
BX51, Olympus) at 40 to 100× magnification, and representative images 
recorded using a QIMAGING camera and QIMAGING Advanced 
software (QIMAGING Diagnostic Instruments). Similarly, survival of 
embryos was assessed visually at 24-h intervals up to 7 days by light 
microscopy. The criterion for embryonic survival was the presence of 
cardiac contractions.
Apoptosis Assay
Zebrafish embryos were incubated for 1 h in embryo medium containing 
modifiers of the radiation response and exposed to 20 Gy at 24 hpf. Six 
hours after radiation exposure, embryos were stained for 15 min using 5 
μg/mL of acridine orange dye (Sigma) and rinsed five times with embryo 
medium as described previously.19 Zebrafish embryos were imaged with 
QIMAGING camera and iVision software; the images were analyzed 
using ImageJ software.
Detection of ROS
Reactive oxygen species (ROS) levels were measured in dechorionated 
zebrafish embryos in 96-well plates. Embryos (1 embryo/well) were 
treated with either vehicle (embryo medium) or EP (1 mmol/L) or 
CDDO-TFEA (1 μmol/L) in the presence of 5-(and-6)-chloromethyl-
2´,7´-dihydrodichlorofluorescein diacetate (CM-H2DCFA; 500 ng/mL; 
Molecular Probes) followed by radiation exposure at 24 hpf. The
average fluorescence emission at 530 nm following excitation at 490 
nm was detected immediately and 2 h after ionizing radiation exposure 
using a microplate fluorescent reader (BIO-TEK FL 600, BIO-TEK 
Instruments Inc.). To account for radiation-induced ROS in the embryo 
medium results were corrected by subtraction of values obtained in wells 
not containing fish in the presence and absence of pharmacologic agents.
Renal Function Assay
Time-dependent clearance of tetramethylrhodamine-labeled 10-kDa 
dextran (Molecular Probes) was determined as described previously with 
minor modifications.20 Briefly, zebrafish embryos at 24 hpf were exposed to 
ionizing radiation and maintained in embryo medium. At 72 hpf 
embryos were anesthetized using a 1:100 dilution of 4 mg/mL tricaine 
methanesulfonate (Sigma) and dorsally positioned on 3% methylcellulose 
gel. Tetramethylrhodamine-labeled 10-kDa dextran was injected into 
the cardiac venous sinus; embryos were kept at 28.5°C, and imaged at 1 
and 24 h following microinjection. The average fluorescence emission at 
590 nm following excitation at 570 nm was detected at the center of the 
cardiac area, and the relative intensity was measured using a Leica micro-
scope (Leica Mikroskopie & Systeme GmbH). Images were transformed 
into grayscale and evaluated with NIH ImageJ software as described.20
Morphologic Analysis of the Gastrointestinal System
The functional and morphologic integrity of the developing gastro-
intestinal system was assessed in zebrafish embryos using PED6, a 
fluorescent reporter of phospholipase A2 (PLA2) activity. PED6 is a fluoro-
genic substrate for PLA2, which contains a BODIPY FL dye-labeled acyl 
chain and a dinitrophenyl quencher group.21 The cleavage of the dye-
labeled acyl chain by PLA2 within cells lining the intestine unquenches the 
dye and leads to detectable fluorescence in the lumen of the developing 
gastrointestinal tract. PED6 was added to zebrafish embryos at 5 dpf 
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followed by imaging the fish at 6 dpf with the average fluorescence
emission at 540 nm excitation at 505 nm. Images were taken at 6 dpf 
using a Leica microscope and analyzed using the ImageJ software.
Histopathology and Evaluation of Tissue Morphology
Zebrafish embryos were evaluated histopathologically for morphologic 
alterations induced by radiation exposure and potential radioprotective 
effects of EP and CDDO-TFEA with special emphasis on the gastroin-
testinal morphology. Briefly, embryos at 24 hpf were exposed to 0 or 12 
Gy in the presence or absence of either CDDO-TFEA or EP administered 
1 h prior to ionizing radiation. Embryos were sacrificed, fixed by immer-
sion in 4 % paraformaldehyde for 24 h, and then rinsed and placed in 10× 
PBS for another 24 h. Sections were embedded in paraffin, and coronal, 
transverse, and sagittal whole-body sections (4 μm thickness) were gen-
erated. All sections were stained with H&E, mounted on glass slides, and 
examined by light microscope; representative images were taken using a 
QIMAGING camera and iVision software.
NF-κB Reporter Assay
NF-κB reporter assay was done as described by us previously 22 with 
minor modifications. HeLa cells were seeded at 7.5 × 104/mL in DMEM 
supplemented with 10% fetal bovine serum. The cells were cotransfected 
with the pSEAP2-NF-κB vector (BDBioSciences) encoding a secreted 
form of human placental alkaline phosphatase driven by a NF-κB–
responsive promoter and a β-galactosidase expression vector for control 
purposes. Forty-eight hours posttransfection, different NF-κB inhibitors 
(0.5 μmol/L velcade, 5 μmol/L MG-132, 1 mmol/L EP, 1 μmol/L CDDO) 
were added to the cells in serum-free media for 24 h. NF-κB–dependent 
transcription in the absence and presence of recombinant TNF-α (10 ng/
mL; R&DSystems) was determined 72 h posttransfection using the Great 
EscAPe SEAP Reporter System 3, which is based on detection of secreted 
alkaline phosphatase in cell supernatants normalized to β-galactosidase 
activity using the luminescent β-gal detection kit (BDBiosciences).
Reverse Transcription PCR Analysis
Zebrafish total RNA was isolated from 100 embryos per experimental 
condition at 30 hpf (6 h post radiation) using the RNeasy mini kit 
(QIAGEN Sciences) and stored at −80°C. For reverse transcription, total 
RNA was annealed with Oligo(dT) primer (Roche) at 70°C for 5 min 
followed by the incubation at 42°C for 1 h. Reverse transcription reaction 
products were boiled for 2 min followed by incubation on ice for 2 min 
before use. Primer sequences used for amplification of bax, mdm2, p21/
waf-1, and β-actin zebrafish sequences are provided in Supplementary 
Table S1. PCR reaction conditions were 94°C, 60°C, 72°C for 30 s, 30 s, 1 
min, respectively, and 35 cycles with 7 min extension time after the last cycle. 
Thermo Fisher Scientific Taq-polymerase was used in 50 μL PCR reaction 
mix containing 1 μL reverse transcription reaction. PCR reactions were 
analyzed by 1.5% agarose gel electrophoresis.
Statistical Analysis
All experiments were done at least three times with at least 75 embryos
total per experimental group. To determine statistically significant 
differences between groups χ2 tests were done.
Results
Proteasome Inhibitors Radiosensitize Zebrafish Embryos
The proteasome inhibitor PS-341 (Bortezomib/VELCADE) is presently 
the only Food and Drug Administration–approved drug with well-
characterized inhibitory effects on NF-κB activity.18 PS-341 is a small, 
cell-permeable molecule inhibiting proteasome activity in a reversible 
manner. In addition to reducing the activation state of NF-κB by inhibiting 
proteasomal degradation of IκB, PS-341 affects many other pathways 
and targets, leading to high expression levels of several proapoptotic 
proteins in certain experimental conditions.23 In vitro, PS-341 has been 
found to enhance antitumor cell effects of select chemotherapeutic 
agents6,24, tumor cell targeting antibodies25, and ionizing radiation26. 
Yet, little is known about the combined effects of PS-341 and ionizing 
radiation on normal cells and tissues of vertebrate organisms. To address 
this issue we used PS-341 in zebrafish embryos exposed to high doses of 
ionizing radiation as described by us previously.4, 27, 28 We first established 
that treatment of zebrafish with PS-341 alone (dose range, 0–10 μmol/L) 
was nontoxic as assessed by embryo survival and gross morphology during
the first 7 days after fertilization (Supplementary Fig. S1). In contrast, PS-341 
(1 μmol/L) markedly sensitized zebrafish embryos to the lethal effects of 
ionizing radiation when administered 1 hour prior to radiation (Fig. 1A). 
In these experiments zebrafish embryos were exposed at 24 hpf to 20 Gy, 
previously determined to kill 50% of irradiated zebrafish embryos by day 
7 of development.27 In HeLa cells, at the same concentration (1 μmol/L) 
PS-341 abrogated the TNF-α–induced NF-κB activity, whereas it did not 
significantly affect the basal activity (Supplementary Fig. 2A and B).
To ascertain whether radiation sensitization by PS-341 could be replicated 
using other inhibitors of the proteasome we next tested the effects of 
MG132, a nonboronated small molecule inhibitor of the 26S proteasome,29 
on zebrafish survival in the presence and absence of ionizing 
radiation. Similar to PS-341, MG132 was remarkably nontoxic when 
applied as a single agent to zebrafish embryos (dose range, 0–50 μmol/L) yet 
efficiently inhibited TNF-α–induced but not the baseline NF-κB activity 
in HeLa cells when used at 5 μmol/L (Supplementary Fig. 2A and B). 
At this concentration, however, MG132 marginally sensitized zebrafish 
embryos to the lethal effects of 20 Gy ionizing radiation albeit to a lesser 
degree than PS-341 (Fig. 1B). An irreversible proteasome inhibitor 
(lactacystin) at a nontoxic concentration (5 μmol/L) also slightly radio-
sensitized zebrafish embryos in a manner similar to MG132 (Fig. 1C).
These results show that several proteasome inhibitors do not protect normal 
cells and tissues in the developing fish larvae against the deleterious 
effects of radiation. As p53 is a major target of proteasomal degradation 
and enhances ionizing radiation–associated tissue damage in mice30–32 
and zebrafish33, 34 we asked whether the deleterious effects of proteasome 
inhibitors could be linked to p53 stabilization and subsequent induction 
of target genes. Consistent with our earlier observations, ablating 
p53 expression by antisense morpholino oligodeoxynucleotide35 or p53 
function by PFT-α (1 μmol/L) given to zebrafish embryos at 24 hpf34 
markedly improved zebrafish survival after radiation either alone or in 
combination with PS-341 (not shown). However, reverse transcription-
PCR analysis did not reveal increased steady-state mRNA levels of 
the p53 targets p21/WAF1, bax, or the zebrafish ortholog of mdm2 in 
PS-341–treated embryos whereas ionizing radiation led, as expected, to 
elevated transcript levels for these genes (Supplementary Fig. S3). Thus, 
the molecular target(s) responsible for radiosensitization by PS-341 and 
their relationship, if any, to the p53 response remain to be identified.
Radiation Protection of Zebrafish Embryos by the NF-κBp65 
Inhibitor Ethyl Pyruvate
In consideration of the fact that proteasome inhibitors affect multiple 
intracellular pathways in addition to NF-κB and to pinpoint the functional 
contribution of NF-κB to the radiation response of zebrafish embryos, we 
tested the effects of a series of pharmacologic inhibitors of NF-κB activity 
with different mechanisms of action on the radiation response of zebrafish 
embryos. Reducing NF-κB activity by expression of upstream regulator 
6 BODINEJOURNAL 
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Figure 1. Effects of the proteasome inhibitors PS-341 (A), MG132 (B), and lactacystin (C) on the radiation sensitivity of zebrafish embryos. Embryos
were irradiated at 24 hpf and survival was scored every day up to 7 dpf. Results shown represent mean ± SD of triplicate experiments. *, 
statistically significant difference in survival at 6 to 7 dpf.
IκB has previously been shown to cause severe embryonal malformations 
in zebrafish36, 37 and, thus, was not further considered. In addition, 
knockdown of the NF-κBp65 subunit by antisense morpholinos similarly 
caused severe morphologic defects (no tail phenotype) during the first 3 
days of development (Supplementary Fig. S4) consistent with published 
results37 and, thus, was not informative in the context of assaying the 
radiation response. Instead, we used pharmacologic inhibitors that 
disrupt the canonical pathway to NF-κB activation and could be used at 
concentrations that do not interfere with embryonal development. First, 
we tested EP, a ROS scavenger and inhibitor of NF-κBp6538. EP inhibits 
the DNA binding activity of NF-κBp65 by binding to a reactive cysteine 
in the DNA binding site (Cys 38) of NF-κBp6513, which is shared between 
humans and zebrafish (Supplementary Fig. S2C). EP has very recently 
been shown to mitigate deleterious effects of total body irradiation
in mice12. We observed that EP similarly not only protected against 
but also mitigated lethality associated with whole body irradiation of 
zebrafish embryos (Fig. 2A, C, and F). EP was administered at various 
time points ranging from 1 hour prior to radiation exposure to 3 hours 
postirradiation. The ROS scavengers amifostine and DF-1 served as 
positive controls in these experiments as we observed marked protection 
of embryos by these two compounds in earlier work.4, 27 Whereas 
amifostine and DF-1 afforded protection against deleterious effects of 
ionizing radiation when administered prior to or concurrent with 
radiation, neither compound could mitigate the lethal effects of radiation 
when given beyond 15 minutes after ionizing radiation27. In marked 
contrast, EP administered up to 2 hours after radiation significantly 
reduced ionizing radiation–associated lethality (Fig. 2F).
The IKK Inhibitor CDDO-TFEA Mitigates Radiation Effects in 
Zebrafish Embryos
To further address the relevance of NF-κB activation in modulating 
radiation sensitivity of zebrafish embryos we used CDDO-TFEA that 
inhibits NF-κB signaling by interacting with Cys179 of IKKβ, inhibiting 
its activity and preventing phosphorylation and proteasomal degradation 
of IκB39 and, thus, through a molecular mechanism distinct from EP. The 
amino acid sequence around this reactive Cys179 is also highly conserved 
in zebrafish (Supplementary Fig. 2C). CDDO-TFEA protected against 
and mitigated overall lethal effects of radiation in zebrafish embryos 
in a manner similar to EP (Fig. 2B, D , and F). We next determined whether 
mitigation of radiation effects cosegregated with the capacity of the 
compounds under investigation to act as ROS scavengers. This was based 
on the findings that, in addition to directly binding to IKKβ, CDDO has 
been described to induce expression of enzymes catalyzing antioxidant 
reactions in peripheral blood mononuclear cells due to increased nuclear 
accumulation of Nrf2, an oxidant-responsive bZIP transcription factor.40, 41 
Whereas EP is an effective ROS scavenger in irradiated zebrafish embryos, 
CDDO-TFEA did not reduce ROS levels measured 2 hours after radiation 
exposure (Supplementary Fig. S5). Thus, at least the effect of CDDO-TFEA 
on radiation mitigation cannot be ascribed to ROS scavenging, whereas 
in the case of EP, ROS scavenging and NF-κB inhibition may be jointly 
responsible for the beneficial effects of EP in the mitigation setting. Of note, 
the ROS scavengers with no known effect on NF-κB signal transduction 
(amifostine and DF-1) do not mitigate radiation effects if administered 
beyond 15 minutes after ionizing radiation.27 To further probe whether 
IKK inhibition is radioprotective we tested four additional small
molecule IKK inhibitors, i.e. Wedelolactone (IKK inhibitor 2), BMS-
345541 (IKK inhibitor 3) and IKK-2 inhibitors 4 and 5. All four agents 
protected zebrafish embryos against the lethal effects of radiation in a 
manner similar to CDDO-TFEA and EP (Fig. 2E). Moreover, unlike EP 
or CDDO-TFEA, these agents are not known to have antioxidant properties 
and primarily inhibit IκBα phosphorylation by IKKβ (i.e., IKK-2). 
On balance, these results suggest that prolonged and excessive activation of 
the canonical NF-κB pathway is a major contributor to radiation toxicity
in the developing vertebrate organism and that inhibiting this pathway 
may protect the organism against deleterious effects of radiation.
Organ-Specific Radiation Protection by CDDO-TFEA and EP
Having established that EP and CDDO-TFEA provide whole-body pro-
tection against lethal doses of radiation and in consideration of the fact 
that these compounds are in preclinical development, we next determined 
organ-specific radiation protective effects of these two NF-κB inhibitors. 
First, we assessed, by acridine orange staining, organism-wide apoptosis 
in zebrafish embryos determined 6 hours after radiation. Consistent 
with earlier reports 33, we observed increased acridine orange staining 
in the central nervous system and along the body axis of irradiated 
embryos. Both NF-κB inhibitors markedly reduced radiation-induced 
acridine orange staining (Fig. 3). We previously reported that ionizing 
radiation compromised zebrafish kidney function as determined by delayed 
excretion of a fluorescent dextran injected intracardially.27 Treatment with EP 
but not CDDO-TFEA significantly reversed the effect of ionizing radia-
tion on dextran clearance of irradiated embryos to near normal levels, 
suggesting protection against ionizing radiation–induced kidney damage 
(Fig. 4). It is currently unknown whether this effect reflects differences 
in ROS scavenging capacity between the two compounds as described 
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above (Supplementary Fig. S5) or is due to differences in pharmacokinetics 
or pharmacodynamics. In addition, radiation of zebrafish embryos is 
associated with a high incidence of a body axis malformation called “curly-up”
to describe aberrant dorsal curvature of the fish tail. Both CDDO-TFEA 
and EP reduced the incidence of curly-up significantly (Fig. 5).
Finally, we determined the effects of radiation on the developing
gastrointestinal system. This was done in consideration of several prior 
reports suggesting that NF-κB activation protects the gastrointestinal 
tract of higher vertebrates against acute radiation damage.42, 43 Radiation 
protection of the gastrointestinal system was determined in several ways. 
First, we assayed overall gastrointestinal function by scoring “long-term” 
survival of fish irradiated in the presence and absence of EP or CDDO-
TFEA (up to 15 dpf). Fish larvae become dependent on external food 
sources at approximately 6 dpf when the contents of the yolk sac are 
depleted. Significant functional damage to the gastrointestinal system 
will thus lead to death by starvation within 10 days after conception.19 
Conversely, survival of fish beyond two weeks indicates establishment 
of a functionally adequate gastrointestinal system. Both EP and CDDO-
TFEA increased extended survival of zebrafish larvae (Supplementary 
Fig. S6) although this effect was statistically significant only in the case 
of CDDO-TFEA. To address the combined effects of radiation and EP 
or CDDO-TFEA treatment on the developing gastrointestinal system 
further, we determined gastrointestinal lumen formation by use of a 
fluorescent reporter (PED6; ref. 21) that is metabolized and excreted 
through the gastrointestinal system. This analysis revealed severely 
impaired lumen formation of the gastrointestinal system induced by 
ionizing radiation (15 Gy) and partial restoration of lumen formation and 
fluorescent dye excretion by treatment with either EP or CDDO. These 
functional results were complemented by examining the histologic 
appearance of the gastrointestinal system 5 days after radiation exposure 
in the presence and absence of the NF-κB inhibitors under investiga-
tion (Fig. 6). The hindgut mucosal epithelium immediately proximal to 
the cloaca revealed distinct cellular changes associated with sublethal 
ionizing radiation exposure (12 Gy), including irregular shape and 
disorganization of the columnar absorbing cells with redistribution of 
nuclei away from the basal orientation. In addition, decreased goblet cell 
numbers were observed. By contrast, EP and CDDO-TFEA pretreatment 
of irradiated embryos restored, in part, the columnar structure of 
absorbing cells and basal location of nuclei.
Discussion
Our results show that 6 of 6 pharmacologic inhibitors with different 
chemical structures and mode of actions inhibit the canonical pathway 
of NF-κB activation (consisting of IKKβ/IκB/NF-κBp65) and provide 
protection against radiation-induced overall lethality and damage to 
multiple organ systems of the developing zebrafish. By contrast, 3 of 3 
proteasome inhibitors did not afford radiation protection, but radio-
sensitized zebrafish embryos to the lethal effects of ionizing radiation. 
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Figure 2. Protection against and mitigation of lethal effects of radiation by direct NF-κB 
inhibitors. Differential survival of zebrafish embryos  pretreated with EP (A and C) or 
CDDO-TFEA (B and D) and exposed to either 20 or 40 Gy as indicated. E, radiation protection 
of zebrafish embryos exposed to 20 Gy and treated for 1 h prior to irradiation with different 
IKK inhibitors. F, increased survival of irradiated (20 Gy) zebrafish embryos treated with EP 
(1mmol/L) or CDDO-TFEA (1 μmol/L) 2 h post radiation at 24 hpf. Survival was scored at 7 
dpf. All results shown represent mean ± SD of triplicate experiments.*, statistically significant 
differences in survival at 7 dpf between drug-treated and vehicle-treated groups.
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Taking into account that each of the pharmacologic agents used in this 
study is likely to affect targets other than NF-κB, it is remarkable that 
radioprotection cosegregated with interference with activation of the 
canonical pathway to NF-κB. This observation suggests that NF-κB may 
be the relevant target for radiation protection by pharmacologic IKK/
NF-κB inhibition.
Currently, there is no consensus about the functional contribution of 
NF-κB activation to the radiation response.44 Abundant reports of 
radiosensitization of tumor cells in vitro and in vivo by NF-κB inhibition 
are contrasted by relatively few such reports dealing with normal cells. 
The use of genetically engineered mouse models to monitor NF-κB 
dysfunction in normal tissues has been limited due to embryonal lethality 
observed in IKKβ45 and NF-κBp6546 knockout animals. In cases where 
either conditional knockouts were made or transgenic mice were gener-
ated by forced expression of dominant negative regulators to modulate 
NF-κB activation, the interpretation of results is further complicated by 
compensatory adjustments of homeostasis (for review see ref. 47). The 
present study sidesteps the problems inherent to using genetic models 
by examining the effects of pharmacologic agents used at concentra-
tions that reduce but do not abrogate NF-κB activity. The ease of our 
“assay system,” i.e., observation of overall effects of ionizing radiation 
on zebrafish survival as well as effects on specific target organs, allowed 
us to monitor the effects of drug classes grouped according to target 
specificity and mechanisms of action. This approach had the advantage 
to minimize confounding effects due to unknown, off-target effects 
of any pharmacologic agent. By contrast, and as expected, ablating 
NF-κB activity by targeting IKKβ or NF-κBp65 expression using anti-
sense approaches produced a dramatically different outcome as these 
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Figure 3. Reduction of organism-wide apoptosis by EP and CDDO-TFEA treatment 
preradiation and postradiation. Acridine orange (AO) staining of whole embryos was done 
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strong AO staining in the central nervous system and along the body axis induced by radiation 
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CDDO-TFEA- and EP-treated embryos exposed to ionizing radiation. C, PS-341 or MG132 
treatment does not significantly affect AO staining of embryos exposed to ionizing radiation.
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B, quantitative representation of dextran 
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EP or CDDO-TFEA as indicated; results 
are expressed relative to vehicle-treated, 
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significant differences between the ex- 
perimental groups indicated by brackets.
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interventions were associated with embryonic lethality even in the 
absence of genotoxic stress (see Supplementary Fig. S4 and ref. 46). This 
result is consistent with the view that inhibition of excess NF-κB activity 
after lethal irradiation is beneficial whereas blocking NF-κB expression 
and/or activation altogether, as in genetic knockout/knockdown models, 
is deleterious (even in the absence of radiation). This contention is fur-
ther supported by our finding that EP and CDDO-TFEA at the nontoxic 
concentration used here disrupted TNF-α–induced NF-κB activation but 
not basal NF-κB activity in HeLa cells in vitro (Supplementary Fig. S2). 
Importantly, CDDO-TFEA and EP not only protected against but also 
mitigated the lethal effects of radiation. This result is of interest as it 
points to the importance of sustained NF-κB activation consistent with 
inflammatory responses rather than the burst of NF-κB activity observed 
immediately after radiation exposure. It remains to be seen whether 
other anti-inflammatory agents may be used to mitigate radiation dam-
age to normal tissues in the developing embryo.
Interestingly, radiation protection of zebrafish embryos by NF-κB inhibi-
tors extended to the gastrointestinal system whereas previous work using 
genetically modified mice42 and the TLR5 ligand flagellin43 has implicated 
NF-κB activation in radiation protection of gastrointestinal stem cells. The 
reason(s) for this difference are unclear at this point. However, the TLR5 
ligand flagellin exerts pleiotropic stimulatory effects on multiple signaling 
pathways that include NF-κB but also p38, Erk/mitogen-activated protein 
kinase, and potentially, signal transducers and activators of transcription.48 
It has not been reported which of these multiple effects alone or in combi-
nation is at cause for radioprotection provided by flagellin.43 In addition, 
the NF-κB inhibitory effects of both EP and CDDO-TFEA are completely 
reversible, whereas genetic ablation is not and this circumstance 
could affect outcomes of NF-κB activation in reference to gastrointestinal 
function. Our findings are further consistent with the view that excessive 
NF-κB activation, as observed in the context of chronic inflammation, is 
potentially deleterious to the gastrointestinal system49 and, thus, down-
modulating NF-κB activity but not ablating it altogether can be advanta-
geous in certain settings.50 Although the details of these diverse outcomes 
in different model systems remain to be sorted out, our results clearly 
show that reducing NF-κB activity with a variety of compounds with 
different mechanisms of action diminishes radiation-induced damage to 
several organ systems in the developing zebrafish embryo.
In conclusion, the most salient finding of this study is that direct inhibitors 
of NF-κB activity provided effective protection and mitigation against 
overall lethality and specific organ damage caused by ionizing radiation 
in zebrafish embryos. Direct NF-κB inhibitors also exert antineoplastic 
effects in select model systems as shown extensively for CDDO-TFEA 
and derivatives thereof.51–57 These findings are consistent with a 
favorable therapeutic window for NF-κB inhibitors when used in
combination with radiation and, potentially, chemotherapeutic drugs.
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Purpose: The tumor growth kinetics of the human LoVo colorectal xenograft model was assessed 
in response to vandetanib, an orally available receptor tyrosine kinase inhibitor, radiotherapy (RT), 
or irinotecan (CPT-11), as single therapies and in combination.
Methods and Materials: LoVo cells were injected subcutaneously into the right hind limb 
(5x106 cells in 100μL phosphate-buffered saline) of athymic NCR NUM mice and tumors were 
grown to a volume of 200–300mm3 before treatment. Vandetanib was administered at 50 mg/kg 
daily orally for 14 days starting on Day 1. RT was given as three fractions (3x3 Gy) on Days 1, 
2, and 3. CPT-11 was given at 15 mg/kg intraperitoneally on Days 1 and 3. Tumor volumes were 
measured on a daily basis and calculated by measuring tumor diameters with digital calipers in 
two orthogonal dimensions.
Results: All three single treatments (vandetanib, CPT-11, and radiation) significantly slowed 
LoVo colorectal tumor growth. Vandetanib significantly increased the antitumor effects of CPT-11 
and radiation when given in combination with either of these treatments. These treatment
combinations resulted in a slow tumor growth rate during the 2 weeks of vandetanib administration. 
The triple combination of vandetanib, CPT-11, and radiation produced the most marked improve-
ment in response as observed by measurable shrinkage of tumors during the first week of treatment.
Conclusions: The tumor growth delay kinetics observed in this study of the LoVo colorectal 
model suggest concurrent and sustained post-sequencing of vandetanib with cytotoxic therapy 
may be beneficial in tumors of this type. ©2009 Elsevier Inc.
Key Words: Vandetanib, Radiotherapy, CPT-11, LoVo colorectal cancer, 
Angiogenesis inhibitor.
Introduction
Colorectal cancer (CRC) remains one of the leading causes of mortality worldwide. In recent years, 
the most widely used chemotherapy for metastatic CRC, fluoropyrimidine (5-fluorouracil [5-FU]) in 
combination with folinic acid, has been combined with newer, highly active cytotoxic agents. Among 
these agents is the DNA topoisomerase I inhibitor, irinotecan (CPT-11),1 a potent DNA-targeting 
drug used in patients with CRC that is refractory to treatment with fluorouracil and leucovorin. 
This cytotoxic agent is, in turn, being combined with new molecular therapies targeting the tumor 
vasculature and key signaling pathways controlling tumor cell proliferation, angiogenesis, and 
survival in CRC. In this regard, the epidermal growth factor receptor (EGFR) plays an important 
role in CRC tumor growth and progression,2 and cetuximab, a monoclonal antibody specific for 
EGFR, has been approved for use in combination with CPT-11 in patients with EGFR-expressing  CRC 
refractory to CPT-11–based chemotherapy.3 In addition, bevacizumab, a monoclonal  antibody 
specific for vascular endothelial growth 
factor (VEGF-A), a key player in tumor 
angiogenesis in CRC as well as other solid 
tumors, has been approved for the treatment 
of metastatic CRC in combination with 
intravenous 5-FU–based chemotherapies.4 
Despite recent improvements in treatment 
for CRC, a need still remains to improve the 
performance of existing treatments and to 
establish the optimum scheduling and dosing 
of combined therapies.
Vandetanib (ZACTIMA) is an oral receptor 
tyrosine kinase inhibitor that, in recombinant 
enzyme assays, demonstrates potent activity 
against vascular endothelial growth factor 
receptor-2 (VEGFR-2) tyrosine kinase (the half 
maximal inhibitory concentration [IC50]=40 
nmol/L) with additional activity against 
EGFR (IC50=500 nmol/L) and the rearranged 
during transfection (RET) tyrosine kinases 
(IC50=130nM) tyrosine kinases.5–8 Vandetanib 
has orphan-drug status in the United States 
and Europe for medullary thyroid cancer 
(in which RET activity is important) and is 
in Phase III development in non–small-cell 
lung cancer and medullary thyroid cancer. 
Phase II studies are ongoing to investigate its 
efficacy in other tumor types, thyroid cancer, 
hepatocellular carcinoma, and glioblastoma.
Vandetanib has been shown to enhance the 
efficacy of radiotherapy in subcutaneous and 
orthotopic tumor xenograft models.9–13 The 
combination of vandetanib, radiation, and 
current chemotherapeutic agents used in CRC 
treatment has not been studied. Preclinical 
demonstration of efficacy of a combination 
protocol with novel agents plus radiation 
is usually considered crucial before clinical 
evaluation. The purpose of the present study was 
to examine the effect of vandetanib on the radi-
ation response of a colorectal tumor model when 
administered in combination with CPT-11. It was 
hypothesized that simultaneous inhibition of 
VEGFR and EGFR by vandetanib in combination 
with the cytotoxic agent CPT-11 would interact 
to enhance radiation response and tumor control 
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in the human LoVo colorectal tumor cell model. The LoVo colorectal model 
expresses activated EGFR14, 15 and is highly vascularized and therefore is an 
appropriate model to test the hypothesis.
Methods and Materials
Animal and tumor model
LoVo cell suspensions (5x106 cells in 100 μL phosphate buffered saline) 
were implanted subcutaneously into the right hind limbs of 6- to 8-
week-old athymic NCR NUM mice (Taconic Farms, Hudson, NY). A
subcutaneous xenograft model was chosen to facilitate radiation dos-
ing and ease of tumor measurements. Tumors were allowed to grow for
approximately 25 days, until reaching an approximate volume of 200–
300mm3 at the start of treatment (Day 1). All animals were randomized 
among treatment groups.
Drug treatment
Vandetanib (AstraZeneca, Macclesfield, UK) was administered by oral 
gavage at 50mg/kg daily for 14 days, starting on Day 1. Vandetanib 
dosing in this study was based on previous pharmacokinetic studies in 
mouse models predicting relevance of this dosing to clinical drug expo-
sure in human patients.16 CPT-11 was given at 15mg/kg intraperitoneally 
on Days 1 and 3.
Radiation treatment
Irradiation was performed on anesthetized mice using X-rays generated 
by a PanTak, 310 kVe X-ray machine, 0.25mm Cu+1mm Al added filtra-
tion, at 125cGy/min. Dosimetry was performed by an in-the-beam ion-
ization chamber calibrated against a primary standard. Corrections were 
made daily for humidity, temperature, and barometric pressure. Mice 
were anesthetized with a combination of ketamine and acepromazine 
at a concentration of 37.5mg/kg and 0.2mg/kg, respectively, to provide 
25–30 min of sedation. Each mouse was confined in a lead casing with 
its tumor-bearing leg extended through an opening on the side to allow 
the tumor to be irradiated locally. Radiation was administered as three 
daily fractions of 3 Gy each on Days 1, 2, and 3. On days when radiation 
was administered with vandetanib or CPT-1, vandetanib and CPT-11 
were given approximately 2h before radiation, with vandetanib preceding 
CPT-11 administration.
Tumor measurement
Tumors were synchronized to be approximately 250 mm3 at the start of 
treatment (Day 1) and were measured four to five times per week, for 
up to 6 weeks of follow-up, or until they reached 2,000 mm3. Tumor 
size was determined by direct measurement with calipers and calculated 
by the formula: (smallest diameter2 x widest diameter)/2. Tumors were 
not allowed to grow beyond 2,000 mm3 in accordance with Institutional
Animal Care and Use Committee regulations.
In vivo tumor necrosis
Tumors were collected from animals on Day 14 after the start of treat-
ment for fixation and staining with hematoxylin and eosin. The area of 
necrosis was evaluated by image analysis and expressed as the percentage 
of the total tumor area.
Statistical analysis
Tumor growth was analyzed via mixed-effects regression, as previously 
described. The method was used because it does not depend on an 
arbitrary end point target tumor size, but uses the repeated tumor size 
measurements obtained over the entire study period, while appropriately 
handling unbalanced data (i.e., different number of measurements for 
different animals) and the correlation of each animal’s measurements 
over time. Mixed-effects regression yields generalizable parameters of 
interest (e.g., average daily tumor growth rate, tumor doubling time), and 
can investigate treatment interactions and nonlinear patterns of tumor 
growth. The base-10 logarithm of tumor volume was modeled as a func-
tion of time and treatment. Linear or quadratic growth curves over time 
were fitted to the log-transformed data, depending on growth patterns 
in each treatment group. All statistical analyses were conducted in SAS 
9.2 (SAS Institute Inc., Cary, NC, 1999–2001).
Results
The experiment involved three different treatments (vandetanib, CPT-11, 
and radiotherapy), as described above and summarized in Fig. 1. Data 
were collected from a total of 104 animals in eight experimental groups 
(11–16 animals per group) and are summarized in Fig. 2. Starting 
tumor sizes were comparable across groups, with geometric means
ranging from 230 to 257mm3 (p = 0.771). All treatments were well
tolerated in the animals with no observable loss of body weight.
The three single-treatment groups (CPT-11, radiation, or vandetanib), 
as well as the combination of CPT-11 with radiation (Fig. 2) were 
fitted to log-transformed curves, whereas the three remaining groups 
that received combination treatments involving vandetanib showed 
a significantly nonlinear tumor growth and were fitted to quadratic curves.
Figure 3 shows the measured geometric mean tumor size graphically over 
time. Table 1 shows the corresponding calculated tumor growth parameters 
(daily tumor growth rate and tumor doubling time). Table 2 shows p values 
for group comparisons at 7, 14, and 21 days after start of treatment.
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Figure 1. Summary of treatment groups. LoVo cells were implanted 
subcutaneously into the right hind limbs of athymic NCR NUM 
male mice. Mice were randomized into eight experimental groups 
(11–16 animals per group). Vandetanib was administered at 50 mg/
kg daily orally for 14 days, starting on Day 1. CPT-11 was given at 
15 mg/kg intraperitoneally on Days 1 and 3. Radiation was given 
as three fractions (3x3 Gy) on Days 1, 2, and 3.
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The control group had an estimated average daily tumor growth rate 
of 9.9%, corresponding to an average tumor doubling time of about 
7 days (Table 1). All three single treatments resulted in a significant 
inhibition of tumor growth, compared with the control group (average 
daily tumor growth rates: CPT-11: 7.1%, p = 0.015; radiation: 5.6%, 
p = 0.001; vandetanib: 5.0%, p = 0.001). Vandetanib inhibited tumor 
growth significantly more than CPT-11 (p = 0.043), but not radiation 
(p = 0.514); radiation and CPT-11 were not significantly different 
(p = 0.139). The combination of CPT-11 with radiation produced a 
daily tumor growth rate of 5.1%, which was significantly lower than 
CPT-11 alone (p = 0.015) but comparable to radiation alone (p = 0.560). 
There was no significant (additive) interaction between CPT-11 and 
radiation (p = 0.105).
The remaining three groups that received treatment combinations 
involving vandetanib (with either CPT-11 or radiation, or with both 
CPT-11 and radiation), showed significant treatment interactions 
(p = 0.001 for the interaction between vandetanib and CPT-11 and 
between vandetanib and radiation) and nonlinear tumor growth patterns. 
Compared with single-treatment groups, growth was significantly 
delayed (and, in the triple-treatment combination, tumor volume 
actually decreased) early on, but progressively accelerated later, although 
it never exceeded that of the untreated controls (Fig. 3). Because of the 
nonlinearity of tumor growth in these groups, tumor growth parameters 
are not constant over time and comparisons depend on the time point 
referenced. Table 2 shows p values for Days 7, 14, and 21.
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Figure 2. Tumor growth curves in LoVo xenografts treated with vandetanib, irinotecan (CPT-11), and/or radiation. Individual mouse data are 
shown for eight treatment groups (11–16 animals per group), along with fitted group curves. Vandetanib was administered at 50 mg/kg daily 
orally for 14 days, starting on Day 1. CPT-11 was given at 15 mg/kg intraperitoneally on Days 1 and 3. Radiation was given as three fractions 
(3x3 Gy) on Days 1, 2, and 3.
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During the first week of treatment, animals receiving the combination 
of vandetanib with CPT-11 had average daily tumor growth rate of 
less than 3.5%, significantly lower than CPT-11 alone and marginally 
so compared with vandetanib alone (p = 0.001 and 0.058, respectively, 
after 7 days). By the end of the 2-week vandetanib treatment, the 
tumor growth rate in the combination group (4.6%) was still significantly 
lower than for CPT-11 alone (p = 0.015) but comparable to that for
vandetanib alone (p = 0.682). By the third and fourth weeks, tumor 
growth had reached levels similar to those seen in the single-treatment 
groups (Fig. 3, Table 1).
The combination of vandetanib with radiation resulted in a similar 
pattern of nonlinear tumor growth inhibition. After the first 7 days, 
the average daily tumor growth rate of 2.1% was significantly lower 
than for either radiation alone or vandetanib alone (p = 0.005 and 
0.019, respectively). After 14 days, the tumor growth rate in the
combination group had accelerated to 3.4% and was only marginally 
lower than for radiation alone and comparable to that for vandetanib 
alone (p=0.080 and 0.212, respectively). By the third and fourth 
weeks, tumor growth had become similar to that seen in the single-
treatment groups (Fig. 3, Table 1).
Despite delaying tumor growth in the initial weeks, the treatment 
combinations induced only modest levels of tumor necrosis (10–20%), 
with no significant differences between treatment groups (Fig. 4).
The pattern of tumor growth in the group that received the triple-
treatment combination reflected both the interaction between 
vandetanib and CPT-11 and that between vandetanib and radiation
(as mentioned previously). Thus, during the first week, instead of 
the delayed tumor growth seen in the two-treatment combinations, 
tumor volume in the triple-treatment combination actually decreased
(p = 0.001 vs. vandetanib plus CPT-11, and 0.052 vs. vandetanib plus 
radiation). After that time, similar to the two-treatment combinations 
that involved vandetanib, tumor growth started accelerating. By the end 
of the third week, tumor growth in the triple-treatment combination 
group was similar to that in the two-treatment combination groups 
involving vandetanib, and by the fourth week, it was similar to that in the 
single-treatment groups.
Discussion
Relatively little is known about the antitumor effects of combining
cytotoxic drugs, radiotherapy, and novel targeted therapies that specifically 
interfere with signaling pathways controlling cancer proliferation, angio-
genesis, and survival. In the present study, vandetanib, a potent inhibitor 
of both VEGFR and EGFR signaling, was combined with CPT-11 or radia-
tion, to determine if greater anti-colorectal tumor activity can be obtained. 
This study demonstrated that all three single treatments (vandetanib, 
CPT-11, and radiation) significantly slowed LoVo colorectal tumor 
growth. Previous studies with single-agent vandetanib demonstrated 
that chronic oral administration reduced tumor vascularity and tumor 
growth in a variety of xenograft models, including CRC.7, 17 In the clinic, 
the safety and tolerability of vandetanib has been demonstrated in 
patients with advanced colorectal cancer as well as other solid tumors.18 
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Figure 3. Estimated geometric mean tumor volume over time in 
LoVo xenografts treated with vandetanib, CPT-11, and/or radiation. 
Vandetanib was administered at 50 mg/kg daily orally for 14 days, 
starting on Day 1. CPT-11 was given at 15 mg/kg intraperitoneally 
on Days 1 and 3. Radiation was given as three fractions (3x3 Gy) 
on Days 1, 2, and 3.
Table 1. Estimates of the average daily tumor growth rate and average tumor doubling time, by treatment group
Time (days)
  1 7 14 21 28 35 __________ __________ __________ __________ __________ __________
 %Δ(T2x) %Δ(T2x) %Δ(T2x) %Δ(T2x) %Δ(T2x) %Δ(T2x)
CTR       9.9   (7.4)   
CPT-11       7.1 (10.2) 
RT      5.6 (12.7) 
VAN      5.0 (14.3)  
CPT-11 + RT      5.1 (13.9) 
VAN + CPT-11    1.9 (37.1)  3.2 (22.2)  4.6 (15.5)  6.0 (11.9)  7.4 (9.7)  8.9 (8.2) 
VAN + RT 0.9 (75.4)  2.1 (33.4)  3.4 (20.9) 4.7 (15.2)  6.0 (11.9)  7.3 (9.8)
VAN + CPT-11 + RT   -2.1 N/A  0.0 N/A  2.4 (28.7)  4.9 (14.5)  7.4 (9.7)  9.9 (7.3)
%Δ: estimated average daily rate of increase/decrease of tumor volume (%).
T2x: estimated average doubling time of tumor volume (in days).
N/A: not applicable (tumor shrinks or is stable).
CTR, CPT-11, RT, VAN, and CPT-11+VAN groups had log-linear tumor growth, so their parameters were constant over time. The remaining
groups did not have log-linear tumor growth, so their parameters were changing over time.
†
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Vandetanib induced manageable normal tissue toxicities related to 
inhibition of EGFR and VEGFR signaling such as diarrhea, rash, and 
hypertension.19, 20 The effect of combining radiation and vandetanib on 
normal tissue is currently unknown, however it has been shown in both 
preclinical and clinical trials that use of VEGF inhibitors with radiation 
may result in higher rates of normal tissue toxicity such as induction 
of thrombosis, hemorrhage, and bowel toxicities.21–23 In contrast, it was 
postulated that combination of radiotherapy with inhibitors of angio-
genesis may actually decrease these risks because radiotherapy has been 
used to prevent hemorrhage.24 Overall, the investigation of agents such 
as vandetanib in combination with radiation in normal tissue is lacking, 
and thus will be a major focus in the future.
As previously discussed, single-agent vandetanib has dual tyrosine 
kinase inhibitory activity against VEGFR-2 and EGFR, which allows 
it to target two key pathways responsible for tumor growth (i.e., tumor 
angiogenic signaling, tumor cell proliferation). It has been speculated 
that dual suppression may be critical for sustained suppression of tumor 
growth, especially because the EGFR and VEGFR pathways are linked 
and exhibit cross-talk.25 In addition, vandetanib can also enhance the 
antiproliferative activity of selective EGFR inhibitors such as cetuximab, 
thereby potentiating suppression of EGFR signaling.17
The present study confirmed that vandetanib, chronically administered 
over 2 weeks, slowed tumor growth in a colorectal tumor model, and, 
under the dosing conditions of this study, slowed tumor growth to 
a greater extent than CPT-11 alone and to a similar level to radiation 
alone. Moreover, vandetanib significantly increased the antitumor effects 
of CPT-11 and radiation, when given in combination with either of these 
treatments. In particular, these treatment combinations resulted in a slow 
tumor growth rate during the 2 weeks of vandetanib administration. These 
results confirm an earlier study by Troiani et al.,26 in which vandetanib 
Radiotherapy
Table 2. P-values for comparisons of treatment groups, on days 7, 14, and 21, after the start of treatment
 Day 7  Day 14  Day 21
CTR 
CPT-11   0.015 vs. CTR; 0.139 vs. RT; 0.043 vs. VAN
RT  0.001 vs. CTR; 0.139 vs. CPT-11; 0.514 vs. VAN 
VAN  0.001 vs. CTR; 0.043 vs. CPT-11; 0.514 vs. RT 
CPT-11 + RT   0.001 vs. CPT-11; 0.560 vs. RT
VAN + CPT-11  0.001 vs. CPT-11; 0.058 vs. VAN  0.015 vs. CPT-11; 0.682 vs. VAN  0.346 vs. CPT-11; 0.395 vs. VAN
VAN + RT 0.005 vs. RT; 0.019 vs. VAN  0.080 vs. RT; 0.212 vs. VAN  0.496 vs. RT; 0.830 vs. VAN
VAN + CPT-11 + RT  0.001 vs. CPT-11; 0.001 vs. RT; 0.001 vs. CPT-11; 0.001 vs. RT;  0.011 vs. CPT-11; 0.366 vs. RT;
 0.001 vs. VAN 0.007 vs. VAN 0.917 vs. VAN
 0.001 vs. CPT-11+RT; 0.001 vs. 0.001 vs. CPT-11+RT; 0.017 vs. 0.766 vs. CPT-11+RT; 0.294 vs.
 VAN+CPT-11; 0.052 vs. VAN+CPT-11; 0.407 vs. VAN+CPT-11; 0.868 vs.
 VAN+RT VAN+RT VAN+RT
CTR, CPT-11, RT, VAN, and CPT-11+VAN groups had log-linear tumor growth and therefore comparisons do not depend on time.
The remaining groups did not have log-linear tumor growth and therefore comparisons that involve them depend on time.
Figure 4. Hematoxylin and eosin stained 
sections of LoVo colorectal xenografts. All 
tumors were collected from animals on Day 
14 after the start of treatment. Areas of 
necrosis are denoted by nec. Magnification 
20x. (a) Control (untreated) tumor, showing 
2% necrosis. (b) Tumor from animal after 
administration of last dose of vandetanib, 
showing 15% necrosis. (c) Tumor from 
animal after administration of CPT-11 and 
RT, showing 20% necrosis. (d) Tumor from 
animal after administration of vandetanib and 
CPT-11, showing 10% necrosis.
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(25mg/kg/day) administered in combination with CPT-11 exhibited 
high antitumor activity in HT29-tumor–bearing nude mice. Troiani et al. 
showed a correlation between this dosing schedule and enhanced EGFR 
and VEGFR signal inhibition.
In the present study, the triple combination of vandetanib, CPT-11, and 
radiation produced the most marked improvement in response in the 
LoVo- tumor–bearing mice. The triple treatment produced a measurable 
shrinkage of tumors during the first week of treatment. The combination of
vandetanib, chemotherapy (gemcitabine), and radiation has also been 
previously shown to significantly inhibit tumor progression in a pancreatic 
tumor model.27 Importantly, the present study also investigated the 
kinetics of tumor growth, both during and after a course of treatment. It was 
demonstrated that the addition of vandetanib significantly  enhanced 
the initial antitumor effect of chemo-radiation. However, when vandetanib 
treatment ended, tumor growth returned to near control (untreated) 
levels. Therefore, these data support the rationale of adding an antivascular 
agent to cytotoxic therapies and provide valuable information for the 
design of therapeutic protocols.
The precise mechanisms leading to initial tumor regression with the 
combined therapies in this study are not known. Analysis of interactions 
between cytotoxic agents and vandetanib is complex, given that both 
the tumor cells and the tumor microenvironment are affected. In this 
connection, radiation can kill not only tumor cells but also endothelial 
cells of the tumor vasculature, thereby affecting the radiosensitivity of 
the tumor (28, 29). In addition, cytotoxic agents have mechanisms of cell 
killing that are different from the targeted agent. Both radiation and CPT-11 
kill cells through DNA damage. Both chemotherapy and radiation can 
also alter cellular signaling pathways by inducing EGFR phosphorylation 
and through the growth factor signaling pathway, contribute to tumor 
cell proliferation and survival.30–32 Preclinical studies have also shown that 
cytotoxic therapy alone, such as radiation, can result in intensification 
of angiogenic processes.33 After cytotoxic treatment, upregulation of 
vascular growth factors and their receptors occurs, which contributes 
to tumor recurrence and progression.34 Direct upregulation of VEGF 
after irradiation of various cancer cell lines has been reported.35 Radia-
tion also induces transient tumor hypoxia which results in upregulation 
of hypoxia inducible factor-1 (HIF-1) which can stimulate VEGF and 
VEGFR-2 expression. Therefore, simultaneous inhibition of both VEGFR 
and EGFR signaling through chronic administration of vandetanib in 
combination with cytotoxic therapy is expected to suppress the upsurge 
in pro-proliferative and angiogenic signaling resulting from CPT-11 and 
radiation-induced EGFR and VEGF. This suppression will thereby lead 
to inhibition of vascular protective mechanisms and growth factor
mechanisms contributing to tumor regrowth.
The increased tumor growth that was seen in this study after discon-
tinuation of vandetanib suggests that inhibition of angiogenic and pro-
proliferative signaling is readily reversed. The current observations are in 
agreement with a number of both preclinical and clinical studies showing 
that tumors can adapt to anti-angiogenic treatment by undergoing 
‘‘evasive resistance’’ to angiogenesis inhibitors.36 Mechanisms of resistance 
include upregulation of alternative proangiogenic signaling pathways as 
well as recruitment of bone marrow–derived proangiogenic cells.37, 38
In addition, administration of vandetanib itself has been observed to 
increase VEGF production in certain cancer cell lines as well as in tumor 
xenografts,39, 40 thereby suggesting an additional contributing mechanism 
to tumor relapse. More studies will be needed to determine whether addi-
tional angiogenic pathways may be induced by triple modality treatment.
Conclusions
The results of this study provide a scientific rationale for testing the 
combination of vandetanib, CPT-11, and radiation in patients with 
CRC. Although the best schedule and sequencing for this triple modality 
treatment has yet to be determined, the tumor growth delay kinetics 
observed in this study suggest that improvement in colorectal 
tumor response can be obtained by concurrent and sustained post-
sequencing of vandetanib with cytotoxic therapy, keeping in mind 
that prolonged chronic administration of the receptor tyrosine kinase 
inhibitors may lead to the development of resistance and the requirement 
for additional therapeutic agents as seen with other targeted agents, 
such as imatinib and gefitinib.41, 42
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Abstract
Background: Locoregional recurrence (LRR) is an important factor after pancreaticoduode-
nectomy (PD) for pancreatic cancer. IORT administered to the resection bed may improve local 
tumor control. 
Methods: We performed a retrospective analysis of patients who underwent PD at Thomas 
Jefferson University Hospital (TJUH) between 1995 and 2005 to identify patients who underwent 
resection with and without intraoperative radiation therapy (IORT). Data collected included age, 
gender, complications, margin status, stage, survival, and recurrence. Unadjusted analyses of 
the IORT and non-IORT groups were performed using Fisher’s chi-square method for discrete 
variables and Wilcoxon Rank Sum test for continuous variables. To account for biases in patient 
selection for IORT, a propensity score was calculated for each patient and adjusted statistical 
analyses were performed for survival and recurrence outcomes. 
Results: Between January 1995 and November 2005, 122 patients underwent PD for perimpullary 
tumors, including 99 pancreatic cancers. Of this group, 37 patients were treated with IORT, and 
there was adequate follow-up information for a group of 46 patients who underwent PD without 
IORT. The IORT group contained a higher percentage of Stage IIB or higher tumors (65%) 
than in the non-IORT group (39.1%), though differences in stage did not reach significance 
(p = 0.16). There was a non-significant decrease in the rate of LRR in patients who had IORT (39% 
non-IORT vs. 23% IORT, p = 0.19). The median survival time of patients who received IORT was 
19.2 months, which was not significantly different than patients managed without IORT, 21.0 
months (p=0.78). In the propensity analyses, IORT did not significantly influence survival or 
recurrence after PD. 
Conclusions: IORT can be safely added to management approaches for resectable pancreatic 
cancer, with acceptable morbidity and mortality. IORT did not improve loco-regional control and 
did not alter survival for patients with resected pancreatic cancer. IORT is an optional component 
of adjuvant chemoradiation for pancreatic cancer. In the future, IORT may be combined with 
novel therapeutic agents in the setting of a clinical trial in order to attempt to improve outcomes 
for patients with pancreatic cancer.
Surgical resection is an essential component 
in the therapeutic approach to patients with 
localized pancreatic cancer. Despite refine-
ments in surgical technique, local and distant 
recurrences are common. Long-term survival 
rates are low for patients with resectable 
tumors, with 15-20% 5-year survival reported 
among patients who undergo pancreatico-
duodenectomy (PD) alone.1, 2 In a review of 
resection margins of 72 patients who under-
went PD, Willett et al. detected a positive mar-
gin in 51% of cases; this factor was associated 
with inferior survival and local control when 
compared with those patients with negative 
surgical margins.2 Although there is controversy 
regarding the appropriate components of 
adjuvant management of resected pancreatic 
cancer,3-7 outcomes achieved after surgery 
alone continue to be poor; therefore, the need 
remains for adjuvant therapy to improve local 
control and survival.3-8 In the United States, 
adjuvant chemoradiotherapy (CRT) is performed 
as part of the standard therapeutic paradigm, 
based on the recurrence patterns of pancreatic 
cancer after surgery.8, 9
Intraoperative radiation therapy (IORT), the 
delivery of a single, large dose of irradiation at 
the time of surgery, was developed in order 
to administer higher doses of irradiation while 
displacing or shielding adjacent normal tissue 
structures from radiation exposure .10 In pancreatic 
cancer, IORT has been offered for unresect-
able tumors to provide local tumor control 
and palliation of pain,11-16 and for resectable 
tumors in an effort to improve local control 
and survival after PD.11-19 Although a definitive 
survival benefit has not been observed, 
improvement of local control by IORT at the 
time of PD for resectable pancreatic cancer is
supported by retrospective data, as well as by a 
prospective, randomized trial conducted at the 
National Cancer Institute (NCI).19-21
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At our institution, IORT has been offered since 1986 in a dedicated 
operating suite located in the radiotherapy department for patients with 
either resectable or unresectable pancreatic cancer. IORT was considered for 
all patients undergoing PD at our institution until 1998. Since then, IORT 
has been reserved for patients with larger tumors with higher risk of 
positive margins, as visualized by the surgeon on preoperative imaging. 
Prior reports from our institution have described outcomes of patients 
who received IORT for resectable and unresectable pancreatic cancer 
prior to 1995.13, 22 The current study evaluates outcomes for patients who 
received treatment for resectable pancreatic cancer from 1995 to 2005. 
As a result of physician bias for the use of IORT in more advanced-
stage pancreatic cancer at our institution, it was not possible to identify 
a comparative group of patients for use in a matched pair analysis. 
Therefore, in order to account for the biases inherent in the nonrandom 
treatment assignment for patients in the current study, analyses of
survival and recurrence were adjusted using propensity scoring.23 In this 
way, we attempted to minimize the influence of confounding patient- 
and tumor-related variables in order to assess the contribution of 
IORT to local tumor control and survival of patients with localized, 
resectable pancreatic cancer treated at our institution. 
Materials & Methods
A prospective tumor registry database was searched to identify all 
patients who underwent PD at Thomas Jefferson University during 
1995-2005. The study was performed with approval of the institutional 
review board at Thomas Jefferson University. These patients were 
further divided into those who did and did not receive IORT. We
collected data regarding age, gender, margin status, stage, survival and 
recurrence. Loco-regional recurrence (LRR) was defined as recurrence 
within the tumor bed or regional lymph nodes. Systemic recurrence 
(SR) consisted of recurrence in the liver, peritoneum, lungs, bone, or 
other distant site. Overall survival (OS) and time to LRR were measured 
from the date of surgery. Given the institutional bias towards IORT for 
larger tumors during much of the study period, a difference between 
treatment groups was anticipated in the statistical analysis. A propensity 
score, a statistical method to adjust for nonrandom treatment decisions 
in observational studies, was also calculated for each patient using a 
logistic regression model.23 
Treatment Policy
All patients were treated according to institutional treatment policies 
during 1995-2005. As a general rule, IORT was considered for all 
patients prior to 1998 and subsequently for patients with larger tumors 
based on review of preoperative imaging by the attending surgeon. For 
these patients, surgery was performed in an operating room located 
in the radiation oncology department, an arrangement selected to 
facilitate IORT delivery. IORT was delivered using 6-15 MeV electrons 
and cone sizes selected in order to deliver a dose of 10-20 Gy to a field 
encompassing the pancreatic tumor bed within the 90% isodose line. 
Regional lymph nodes were not included in the target volume for 
most cases. The cone size, treatment set-up, and immobilization were 
selected in order to treat the target volume while minimizing exposure 
of adjacent normal tissue structures. The standard dose, 15 Gy, was 
reduced to 10 Gy for either large treatment volumes or margins that 
were clearly negative. For larger tumors, 20 Gy was often prescribed. 
In cases where adjuvant external beam radiation therapy (RT) was 
also delivered, a dose of 45-50.4 Gy was prescribed using a conformal, 
four-field radiation technique.
Statistical Analysis
Simple descriptive statistics were generated, and unadjusted associations 
with IORT were determined using Fisher’s Chi Square test for categorical 
variables and using the Wilcoxon rank sum test for continuous variables. 
The propensity score, which was calculated for all patients included in 
the analysis using a logistic regression model, included resection status, 
AJCC Stage, differentiation, age, race, and sex. Propensity scores were 
incorporated as a categorical variable in the statistical analyses based 
on quartiles. The association of IORT with the primary outcome of 
survival was determined using a Cox proportional hazards model. 
The Cox proportional hazards model included IORT, the propensity 
score (by quartile), adjuvant chemotherapy, and adjuvant radiotherapy. 
Association of IORT with the secondary outcomes of any recurrence, 
loco-regional recurrence, and systemic recurrence was determined using 
logistic regression models. Included in the logistic regression models for 
adjusted analyses of recurrence were IORT, the propensity score (by 
quartile), adjuvant chemotherapy, and adjuvant radiotherapy.
Results
From January 1995 to November 2005, 122 patients underwent PD for 
periampullary tumors, including 99 pancreatic cancers. We identified 
37 patients with pancreatic cancer who were treated with IORT. Among 
the remaining 62 patients with pancreatic cancer treated without IORT, 
adequate follow-up data could be obtained for 46 patients, who comprised 
the non-IORT group used in the statistical analyses. The median patient 
age in the IORT group was 64 years (inter-quartile range, 55-70 years); in 
the non-IORT group, the median age was 67 years (inter-quartile range, 
59-74 years). The IORT group demonstrated non-significant trends 
toward more advanced stage tumors (p=0.16) and a higher rate of positive 
margins (p=0.26). A higher proportion of patients received adjuvant 
chemotherapy after PD with IORT than after PD alone (p=0.05) (Table 1). 
There were 2 perioperative deaths in the IORT group (5.4%) and none in 
the non-IORT group (p=0.20). Rates of perioperative complications were 
similar, 46% in the IORT group versus 40% in the non-IORT group. The 
median follow-up among surviving patients was 21 months. 
Recurrence and Survival
Recurrence data were available for 80% of all patients, including 30 IORT 
patients (81%) and 36 non-IORT patients (78%). Rates of loco-regional 
recurrence (LRR) (Figure 1) or any recurrence (Figure 2) were not 
significantly different between the IORT and non-IORT groups. Among 
non-IORT patients, there was loco-regional recurrence (LRR) in 39%, 
systemic recurrence (SR) in 50%, and any recurrence in 69%. In the 
IORT group, LRR in 23%, SR in 57% of patients, with, and recurrence 
was observed in 67% (Table 2). Liver metastases were the most common 
form of SR. LRR in the absence of SR was observed in 2 patients (7%) 
in the IORT group and in 7 patients in the non-IORT group (19%). LRR 
was not significantly different between the IORT and non-IORT groups 
(p=0.20). The median survival time of patients undergoing IORT was 
19.2 months, which was not significantly different than patients man-
aged without IORT, 21.0 months (p=0.49) (Figure 3). 
Propensity Score Analysis
In the adjusted, propensity score analysis of the association of IORT 
with survival, IORT was not associated with significant improvement of 
survival time (Table 3). The Cox regression model for survival included
IORT status with propensity score (by quartile), as well as adjuvant RT and 
chemotherapy. The propensity score-adjusted analyses of the association 
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of IORT with LRR, with SR, and with any recurrence were conducted 
using logistic regression models (Table 4). After adjusting for propensity 
score quartile and for adjuvant therapies, IORT did not influence recur-
rence rates after PD for pancreatic cancer. A non-significant trend towards 
higher rates of any recurrence was noted for propensity scores in the third 
(OR 9.66, p = 0.14) or fourth quartile (OR 9.64, p = 0.15).
Discussion
Local control was not significantly different between the two groups, 
IORT and non-IORT, evaluated in the current series. Although the 
current study is limited by its retrospective design and institution bias 
towards treating more advanced tumors with IORT, an attempt was 
made to account for nonrandom allocation of patients into the IORT 
and non-IORT groups by using propensity score values in adjusted 
statistical analyses of the association of IORT with survival and recurrence. 
Adjuvant chemotherapy was administered to more patients in the 
IORT group. Although information concerning decision-making was 
not available, the increased rate of chemotherapy may be related to the 
presence of more advanced tumors in the IORT group. Despite the trends 
toward more advanced-stage tumors and positive resection margins in 
the IORT group, similar local control rates were observed. 
The disparities in stage and margin status in the current study may have 
obscured any potential local control benefit of IORT, as these factors have 
been reported to negatively influence survival for patients with resected 
pancreatic cancer.24, 25 Prior retrospective, single-institution reports 
suggest that IORT improves local control after PD by approximately 
30%.19, 21 In this study, LRR was 50% less in the IORT group. In the 
prospective, randomized trial conducted at the NCI, local control 
improved from 0% to 33% with the addition of IORT.20 In a recent series 
Table 1. Tumor- and treatment-related characteristics for 
37 IORT patients and 46 non-IORT patients with resected 
pancreatic cancer.  
Factor PD + IORT[n (%)]
PD (No IORT) 
[n (%)] p value
Stage
I
IIA 
≥IIB
7 (19)
6 (16)
24 (65)
16 (35)
12 (26)
18 (39)
0.16
Margin Status
RO
R1/R2
21 (57)
16 (43)
32 (70)
14 (30)
0.26
Grade 
(n=81)
Well
Moderate
Poor
7 (19)
21 (58)
8 (22)
8 (18)
25 (56)
12 (27)
0.91
Adjuvant 
Chemotherapy
(n=79)
Yes
No
26 (84)
5 (16)
27 (63)
16 (37)
0.05
Adjuvant EBRT
(n=75)  
Yes
No
23 (74)
8 (26)
29 (66)
15 (34)
0.44
1.0
0.6
0.2
0.8
0.4
400
Time to Recurrence (months)
305 20 3510 2515
Treated with IORT
Treated without IORT
p = 0.20
Figure 1. Kaplan-Meier plot of locoregional failure for patients 
treated with (solid line) and without (dashed line) IORT (p = 0.20).
Table 2. Location of first recurrence. Thirty patients in the IORT 
group and 36 patients in the non-IORT group were included in 
the recurrence analysis, based on availability 
of data to determine site of recurrence.
Site of First Recurrence PD + IORT
[n (%)]
PD (No-IORT)
[n (%)]
Locoregional 7 (23) 14 (39)
 Tumor Bed 6 (20) 8 (22)
 Lymph Node 4 (13) 10 (28)
 Locoregional-Only 2 (7) 7 (19)
Systemic 17 (57) 18 (50)
 Liver 11 (37) 11 (31)
 Lung/Pleura 4 (13) 7 (19)
 Systemic-Only 14 (47) 11 (31)
1.0
0.6
0.2
0.8
0.4
Treated with IORT
Treated without IORT
p = 1.0
400
Time to Recurrence (months)
305 20 3510 2515
Figure 2. Kaplan-Meier plot of recurrence (any site) for patients 
treated with (solid line) and without (dashed line) IORT (p = 1.0).
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from the City of Hope National Medical Center, isolated local recur-
rences were reduced from 33% to 5% with the addition of IORT, which 
is comparable to the rate of isolated LRR in the current report (7%).24 
Reni et al. reported a similar alteration of recurrence patterns, with 15% 
local-only recurrences with IORT versus 33% without IORT.26 The 
cumulative evidence, including one prospective randomized trial and a 
few prospective studies, supports a local control benefit for IORT in
resectable pancreatic cancer. An improvement in local control has not 
been shown to translate into a clinical benefit in survival outcomes, 
including in this study. Although a propensity score analysis was
performed in the current study to evaluate the influence of IORT on 
recurrence rates after PD, the limited size of the patient population may 
have restricted our ability to detect a significant positive effect. 
The survival rates were not different between the IORT and non-IORT 
groups in the current series, which is consistent with the results of 
the prospective NCI study.20 Given the propensity of pancreatic cancer 
towards distant metastatic recurrence, it is not surprising that a measurable 
increase in local control did not produce a corresponding improvement 
of survival.27 Although some authors report a survival benefit 
from IORT for resectable pancreatic tumors at their institutions, the 
literature  does not consistently support this claim, and detection of a potential small survival benefit would require a large trial.19, 22, 24, 26, 28, 29 
Regardless of the absence of improved survival, the problem of 
locoregional control does leave open a place for radiation therapy after 
PD, and IORT is an effective technique to boost radiation dose around 
the resection bed while displacing sensitive adjacent organs.8, 10, 17, 30 A 
recent analysis of the Surveillance, Epidemiology, and End Results data-
base revealed a survival benefit to the addition of adjuvant radiotherapy 
after PD, and radiation therapy remains an important component of 
adjuvant strategies in the United States.25 Results recently published 
from the Radiation Therapy Oncology Group (RTOG) trial 9704, the 
first cooperative group study to require prospective quality assurance of 
radiotherapy, suggest a benefit to the addition of gemcitabine to adjuvant 
CRT after PD. The rates of first relapse in local and regional sites in the 
experimental arm of RTOG 9704 were 23% and 7%, respectively..31 
Importantly, the addition of IORT after PD did not increase peri-
operative complication rates significantly in the current series, which is 
consistent with the earlier experience from our institution.22 Although 
late complications have been reported after IORT for pancreatic cancer, 
our results and other reports suggest that IORT may be delivered 
safely in combination with surgical resection.24, 26, 28, 32, 33-37 Selection of 
Table 2. Location of first recurrence.  Thirty patients in 
the IORT group and 36 patients in the non-IORT group were 
included in the recurrence analysis, based on availability 
of data to determine site of recurrence.
Site of First Recurrence PD + IORT
[n (%)]
PD (No-IORT)
[n (%)]
Locoregional 7 (23) 14 (39)
 Tumor Bed 6 (20) 8 (22)
 Lymph Node 4 (13) 10 (28)
 Locoregional-Only 2 (7) 7 (19)
Systemic 17 (57) 18 (50)
 Liver 11 (37) 11 (31)
 Lung/Pleura 4 (13) 7 (19)
 Systemic-Only 14 (47) 11 (31)
Table 3. Cox proportional survival hazard model for 
the association of IORT, propensity score, and other 
factors with survival time in months.
Estimate
Standard
Error Chi-Square
Hazard 
Ratio p
IORT    -0.34 0.35 0.94 0.71 0.33
Adjuvant 
Chemo-
therapy
0.51 0.73 0.48 1.66 0.49
Adjuvant 
Radiotherapy
-1.05 0.68 2.39 0.35 0.12
Propensity Score (vs. 1st Quartile)
2nd Quartile
3rd Quartile
4th Quartile
   -0.68
0.55
0.58
0.45
0.49
0.47
2.35
1.26
1.56
0.50
1.73
1.79
0.13
0.26
0.21
Table 4. Logistic regression models of the association of IORT, 
propensity score, and other factors, with the outcomes of any 
recurrence, locoregional occurrence, and systemic recurrence.
Odds Ratio 95% CI p
Any Recurrence
IORT 0.77 (0.19, 5.20) 0.72
Adjuvant Chemotherapy 1.69 (0.15, 19.29) 0.67
Adjuvant Radiotherapy 1.11 (0.11, 11.68) 0.93
Propensity Score (vs. 1st Quartile)
2nd Quartile
3rd Quartile
4th Quartile
1.22
9.66
9.64
(0.33, 4.52)
(0.47, 197.40)
(0.46, 203.31)
0.76
0.14
0.15
Locoregional Recurrence
IORT 0.41 (0.10, 10.30) 0.23
Adjuvant Chemotherapy 0.49 (0.02, 11.37) 0.65
Adjuvant Radiotherapy 1.74 (0.86, 35.51) 0.72
Propensity Score (vs. 1st Quartile)
2nd Quartile
3rd Quartile
4th Quartile
0.39
5.13
3.32
(0.02, 7.47)
(0.73, 36.03)
(0.46, 23.93)
0.53
0.10
0.23
Systemic Recurrence
IORT 0.99 (0.28, 3.52) 0.99
Adjuvant Chemotherapy 0.40 (0.03, 6.42) 0.52
Adjuvant Radiotherapy 1.30 (0.10, 16.96) 0.84
Propensity Score (vs. 1st Quartile)
2nd Quartile
3rd Quartile
4th Quartile
1.11
0.91
0.59
(0.23, 5.40)
(0.16, 5.13)
(0.10, 3.50)
0. 90
0.91
0.56
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radiation doses for IORT was influenced by seminal, preclinical canine 
experiments performed at the National Cancer Institute that provided 
an understanding of normal tissue tolerances, including surgically-
manipulated tissues, for IORT.38,39 These studies created a foundation for 
the rational delivery of IORT in humans, so it should not be surprising 
that clinical studies have shown these RT doses to be safe and feasible.
Based on recent practice changes at our institution, IORT will be offered 
infrequently for patients with localized pancreatic tumors, in favor of 
alternate adjuvant strategies after surgical resection. Novel adjuvant 
therapy combinations tested in recent institutional and cooperative 
group trials have focused on systemic treatments aimed at reducing 
metastatic recurrences after PD, as distant dissemination is a dominant 
cause of mortality for patients with pancreatic cancer.27, 40 However, 
adjuvant external beam radiation therapy remains an important
component of management, based on recognition of the parallel 
importance of preventing local recurrence.2, 25 Although the current 
study does not support its continued use, it is reasonable that IORT is 
considered as a potential component of adjuvant RT strategies. Should 
adjuvant systemic therapies for resected pancreatic cancer improve in the 
future, LRR may become a more significant concern. IORT may become a 
more important tool for maximizing loco-regional control in that situation. 
In summary, the current study demonstrates that IORT is a safe addition 
to PD and standard adjuvant therapies, with the intention of improving 
local control after PD for patients with resectable pancreatic cancer. 
Although local control was not significantly improved with the addition 
of IORT in the current study, the significantly higher number of more 
advanced stage tumors and a trend towards more positive surgical margins 
in the IORT patients may have influenced the results of our comparative 
analyses. We cannot currently recommend routine use of IORT in the 
adjuvant setting for patients with resected pancreatic cancer. Future clinical 
trials with novel therapeutic agents may include IORT in combination 
with resection, adjuvant external beam radiotherapy, and systemic agents
in order to improve outcomes for patients with pancreatic cancer. 
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Flexible Needle-Tissue Interaction 
Modeling With Depth-Varying Mean 
Parameter: Preliminary Study
Abstract
Flexible needle steering has aroused a lot of research interest in recent years. It has the potential to 
correct targeting errors, which may be caused by needle bending, tissue deformation, or error in 
insertion angle. In addition, control and planning based on a steering model can guide the needle 
to some areas that are currently not amenable to needles because of obstacles, such as bone or 
sensitive tissues. Thus, there is a clear motivation for needle steering. In this paper, a spring–beam–
damper model is proposed to describe the dynamics during the needle–tissue contact procedure. 
Considering tissue inhomogeneity, depth-varying mean parameters are proposed to calculate the 
spring and damper effects. Local polynomial approximations in finite depth segments are adopted 
to estimate the unknown depth-varying mean parameters. Based on this approach, an online 
parameter estimator has been designed using the modified least-square method with a forgetting 
factor. Some preliminary experiments have been carried out to verify the steering model with the 
online parameter estimator. The details are given in this paper. Finally, conclusions and future 
studies are given at the end.
Index Terms: Depth-varying mean parameter, needle steering modeling, 
percutaneous surgery, spring–beam–damper model.
I. Background
Medical procedures, such as brachytherapy, biopsies, and treatment injections, require inserting a 
needle to a specific target location inside the human body to implant a radioactive seed, extract a 
tissue sample, or inject a drug. Precise needle placement is very important. Poor placement may 
cause tissue damage, misdiagnosis, poor dosimetry, and tumor seeding. Unfortunately, precise 
needle placement is hard to achieve in real practice. Errors caused by the target movement and 
needle deflection have been observed for a long time.1-4 Yet to date, there are few effective physically 
based needle steering systems existing for correcting the targeting error automatically when it 
is observed. It is interesting to note that during clinic practice, some surgeons make use of a 
combination of lateral, twisting, and inserting motions of the needle under visual feedback from 
imaging systems, such as ultrasound, to correct the targeting errors. Surgeons accomplish this 
from experience, making it difficult to teach and limiting the accuracy to that of human hand/
eye coordination.
Flexible needle steering was first addressed by DiMaio et al.5 using a finite-element model. His 
model was later extended by other researchers to 3-D models.6, 7 In the Medical Image Computing 
and Computer-Assisted Intervention Conference 2005, Daniel Glozman and Moshe Shoham8 
presented a simplified virtual spring model for the needle insertion procedure. Modeling of a 
flexible needle was based on the assumption of quasistatic motion and a third-order polynomial 
was used to calculate the displacement of each element. Compromise had to be made between the 
computational efficiency and the model accuracy.
Needle steering making use of the needle bending has also been explored in the past few years. 
Some researchers have generated needle bending using different strategies, such as incorporating 
a prebent stylus inside a straight canula,9 or a telescoping double canula, where the internal 
canula is prebent.10 Other researchers showed 
that needles with bevel tips bend more 
than symmetric-tip needles.11 Making use 
of this effect, thin highly flexible bevel-tip 
needles using Nitinol were developed, and a 
nonholonomic model was built accordingly 
for steering flexible bevel-tip needles in 
rigid tissues.12 The nonholonomic model, a 
generalization of a 3-D bicycle model, was 
experimentally validated using a very stiff tissue 
phantom. Recent advances in nonholonomic 
path planning include stochastic model-based 
motion planning to compensate for noise 
bias,13 probabilistic models of dead-reckoning 
error in nonholonomic robots,14 a diffusion-
based motion planning to search for a feasible 
path in full 3-D space, and motion planning 
under Markov motion uncertainty using 
dynamic programming to search for a feasible 
route while avoiding obstacles.15
In this paper, a needle steering model is 
proposed for flexible needle steering purpose. 
A spring–beam–damper model is adopted 
to model the dynamics between the lateral 
needlebased force and the corresponding 
lateral needle tip movement with consideration 
of the needle flexibility and tissue deformation. 
Considering the tissue inhomogeneity, depth-
varying mean parameters are proposed to 
calculate the spring and damper effects. Local 
polynomial approximations in finite-depth 
segments are adopted to estimate the unknown 
depth-varying mean parameters. Unlike the 
models proposed in5 and,8 this model takes into 
consideration not only the viscoelastic tissue 
reactions but also the tissue inhomogeneity. 
In the literature, the spring–damper model 
has been adopted by many research groups 
in studying tissue deformation.16–18 But how 
the coupled interaction of the instrument 
and soft tissue is and how to control the 
instrument while in collision with such an 
environment have received little attention. 
Some researchers studied the collision of 
the flexible link with the environment in the 
application of grinding or surface turning 
operation.19,20 They modeled the environment 
as a simple spring–damper system, which was 
assumed to be stationary and was arbitrarily 
placed along the trajectory such that the beam 
would only make contact with it at the tip. In 
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the application of needle steering, the flexible instrument interacts with 
the environment with changing force along the needle body from time 
to time. The situation is much more complicated compared with the
point contact.
Based on the proposed model, an online parameter estimator has been 
designed using the modified least-square method with a forgetting 
factor. Preliminary experiments have been carried out to verify the 
steering model with the online parameter estimator. Results have shown 
its effectiveness. Finally, conclusions and future studies are given at the end.
II. Needle Lateral Steering Force Modeling
 And Analysis
A. Needle Lateral Steering Force Modeling
A spring–beam–damper system, as shown in Fig. 1, is considered in 
this study to model the system dynamics between the lateral steering 
forces acting at the needle base and the corresponding needle tip lateral 
movement during insertion in the soft tissue. The flexible needle is 
assumed to follow the Bernoulli–Euler beam model and is required to 
be clamped tightly at the base. The initial lengths of springs are decided 
by the needle tip trajectory, as shown in the figure. At the beginning, the 
needle is placed next to the tissue. With time progressing on, the needle 
inserts into the tissue. Then, the springs and dampers come into contact 
with the needles and exert forces on it accordingly. The forces of the 
springs at time instant t are determined by the needle body shape at that 
time and the needle tip trajectory; while the forces of the dampers are 
determined by the velocities of the contact points. During this procedure, 
not only the tissue deformation and the needle flexibility, but also their 
interaction effects, should be taken into consideration.
To derive the equations of needle insertion, the following assumptions 
are made.
1) For simplicity, the needle is considered to move only in the XY 
plane. X is the insertion direction and Y is the steering direction.
2) There is no longitudinal compression of the beam and only lateral 
deflection is possible. Furthermore, the lateral deflection of the 
beam is small compared with the length of the beam.
3) The rotational effect of the beam with respect to the local coordinate 
system is neglected.
Under the aforesaid assumptions, the system dynamic equation can be 
derived using Hamilton’s principle as follows:
where T is the kinetic energy, V is the potential energy, and Wnc is the 
work done by nonconservative forces.
A local coordinate system is introduced by the Galilean transformation 
to replace the fixed coordinates (x) with a moving coordinate system 
(x͂), which is attached at the needle base and moves with it. vx is the 
needle insertion velocity, which is assumed to be constant for modeling 
simplicity.
The system kinetic energy T includes the kinetic energy of the fixture 
and the needle, as shown in the first and second terms of the following 
equation (3), while the potential energy V includes the potential energy 
of the needle caused by needle bending (the first term) and the potential 
energy of the springs resulting from the forces between the needle and the 
tissue (the second term), as given in (4). The integration of the difference 
between the needle body positions and the needle tip trajectory gives the 
summation of the elongated or compressed spring length (decided by 
the sign of the difference) at the contact points. Because only the needle 
portion inside the tissue has springs exerting force on it (5), the Heaviside 
unit step function is used to exclude the portion outside the tissue. 
h(x) = L - vx t is the position of the insertion point in the moving 
coordinates system at time instant t. Thus, the potential energy of the 
springs can be calculated using the second term of (4)
Needle position
without deflection Needle body trajectory
Tip trajectory
Figure 1. Mechanism of the needle insertion procedure.
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Here, M is the mass of the fixture that links the needle with the 3-D
motion platform, L is the length of the elastic beam, ρ is the mass per unit 
length of the elastic beam, E is the Young’s modulus of the needle, I is the 
second moment of inertia about the z-axis, k is the stiffness coefficient 
of the spring per unit length, c is the damper coefficient per unit length, 
y is the needle base position in y-axis,  ⋅y(t) is the corresponding velocity 
at time instant t, ω is the deflection of the beam along the needle body at 
time instance t, and  ⋅ω and ω″ are the first and second derivatives of the
beam deflection with respect to time and space, respectively.
The virtual work done by all the nonconservative forces (steering force Fy 
and damping forces), is given by
The equation of motion and the boundary conditions of the system are 
obtained by substituting the aforesaid equations (3), (4), and (6) into (1), 
integrating the resulting equation by parts, and considering that the time 
t1 and t2 are arbitrary and that δy, δω are arbitrary and independent. 
Thus, the equations of motion for the spring–damper system are obtained 
as follows:
where 
Boundary conditions:
To solve the partial differential equations shown in (7) and (8), 
unconstrained modal analysis is adopted in this approach.21 The 
deflection of the elastic beam and the displacement of the fixture are 
expressed, respectively, in terms of n mode shapes using the obtained
φ(x͂), βi, qi (t) as follows:
and accordingly, the position of fixture is given as
where α(t) describes the motion of the center of mass of the total system 
without perturbation, ϕ(x͂) is the shape function that is the space solution 
of the deflection, q(t) is the time-varying amplitude of motion that is the
time solution of the deflection, and β is defined to satisfy 
After some algebraic manipulation (refer to [22] for more details), the 
model is finally obtained as follows:
with
Here, Mt is the total mass of the fixture and needle; Y (t1) = 
      is the needle tip position at time instant t1,
which is time varying and derived from (10)–(12); and Fy is the lateral 
steering force, which acts at the needle base in the y direction.
These partial differential equations can be solved using the explicit 
Runge–Kutta (4, 5) formula, and the Dormand–Prince pair. A Matlab 
simulation program has been composed to simulate this model. With the 
applied needle base force Fy serving as the input of the model, α and qi 
will change with time, thus causing the change of the needle tip position
Y (t1) in the y-axis, which is the output of the model, as well as the tissue 
reaction forces.
B. Local Polynomial Approximation of Depth-Varying Mean Parameters 
Considering the inhomogeneous human tissue and the multiple tissue 
layers that the needle will penetrate through during surgery, here we
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Figure 2. Local polynomial approximations of the parameter functions.
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propose to use depth-varying mean parameters to calculate the spring/
damper reaction forces and use local polynomials to approximate the 
depth-varying mean parameters.
Assumption 1: The spring and damper coefficients are different at 
different depths of the tissue. At each insertion step, the spring/damper 
effects along the needle body that is inside the tissue can be calculated 
using mean spring/damper coefficients θ(s) = [c¯ k¯]T. These mean 
coefficients will vary with each step.
This assumption takes into consideration the inhomogeneous human 
tissue, and at the same time, releases the computation intensity by using 
mean values to calculate the spring/damper forces along the needle body 
at each insertion step. Furthermore, the adoption of the mean values 
guarantees that θ(s) is continuously distributed regardless of the abrupt 
change of the tissue properties, e.g., pathological changes of the tissue, 
or multilayer insertion.
Assumption 2: The depth-varying mean parameters θ(s) can be represented 
by a series of local polynomial approximations in finite segments.
This can be justified using Taylor series expansion. Recall that the functions 
θ(s) can be expanded around certain points s0, as shown next. Here, θ(s) is 
approximated by the first p + 1terms. The last term represents the error due 
to the approximation
From the aforesaid assumptions, we can divide the whole insertion length 
into several segments and adopt piecewise continuous p-order differentiable 
functions θij , i = 1, 2, j = 1, 2, . . . , n to represent the depth-varying mean 
parameter θi(s), i = 1, 2 in each segment, as illustrated in Fig. 2. Here, the
index i refers to the ith parameter (spring or damper coefficient), while 
the index j refers to the jth segment and n is the number of segments. 
The S coordinate system is adopted for convenient representation of the 
parameters. So, the polynomial approximation of θij is represented as 
where l is the length of the segment and p is the order of 
the polynomial. s0,j  refers to the resetting depth at which the jth 
window of the local polynomial approximation for parameter 
θi begins. s0, j  is given by the sequence s0 = {s0,j},  j  =  1 ,  .  .  .  ,  n
and
          where                is the kth depth derivative evaluated at
is  the  unknown  constant  vector  and 
                                        is a column vector.  Notice that
is constant only within each segment [s0,j, s0,j+1), and in general, differs 
from one segment to another for the inhomogeneous tissue.
Therefore, it is possible to use (16) to approximate θij (s) more precisely 
by choosing either a higher order polynomial, that is, p large, or a 
smaller segment l, or both. If we partition the whole insertion length 
into segments with the length of each segment equal to l, then the 
depth-varying function θi(s) can be approximated by a number of 
polynomials θij (s) located in each segment with constant coefficients 
aijk, as shown in (16).
C. Online Parameter Estimator Design
The discretized needle steering model is considered here. The needle 
steering force model can be reorganized as
where
Here, y1 refers to the needle tip trajectory, while y2 is the needle base 
trajectory that is measured to facilitate the computation of the system 
state x.
After some algebraic manipulation, we can get
Rm is the unknown depth-varying mean parameter vector with an 
additional constant 1.
The measured output
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Substituting the polynomial approximations for the depth-varying mean 
parameters, (19) can be represented as
Here, for simplicity, we select the same-order polynomials for the two 
parameters.
The transformation between the s domain and x͂ domain is given by 
under the same assumption that the needle is inserted at constant 
velocity.
To facilitate the computation of the dynamic equation, the dataset s0 = 
{s0 , j}, j = 1, 2, . . . can be converted to the time domain using
In discretized form
Based on this approach, the modified least-square estimation with 
covariance resetting and forgetting factor is adopted to estimate the 
coefficients that take the form
where ˆϑ is the estimated parameter vector, Z is the measurement, λ is the 
forgetting factor, P is the covariance matrix, and K is the gain.
D. Lateral Steering Force Model Validation
1) Material and Method: 
To validate the effectiveness of the proposed steering model, a physical 
experiment has been carried out. The experimental setup, shown in 
Fig. 3, is used to carry out the experiment. The 3-DOF motion platform 
drives the needle into the phantom/animal organ following some 
predesigned trajectory. A 6-DOF force/torque (F/T) sensor is mounted 
at the needle base to measure the needle base force. The needle adopted 
here is a 5-DOF MagTrax needle probe. It is a 130-mm-long needle and 
has a sensor located at the stylet’s proximal symmetric tip. This needle 
tip movement in the 5-DOF, except rotation about the needle axis, can 
be observed in real time via an electromagnetic system called Aurora.
An “active” way of validating the proposed model by steering the needle 
tip to a defined position is infeasible now, since it will require a steering 
strategy, which is our future task. Instead, a “passive” way of validation 
is adopted to show that the model could accurately predict the needle 
tip trajectory when giving some inputs – needle-based lateral forces. The 
detailed validation procedure is described as follows.
The needle is first driven into the prepared phantom by the 3-DOF platform 
following some predetermined trajectories with various insertion speeds. 
The needle tip/base positions and corresponding needle base force data 
are collected during the procedure. These collected datasets are first 
passed through a designed filter to remove the measurement noises and 
smooth the data. After that, the filled datasets go through the online 
parameter estimator to estimate the depth-varying mean parameters. 
At the same time, the model is simulated using the online estimated 
parameters and the collected dataset to predict the output, the needle 
tip position. The output is then regulated using the collected output data 
instead of the simulated ones during the simulation. This regulation 
method can prevent the simulator from accumulating estimation errors, 
which will gradually lead to the divergence of the estimation. At last, the 
simulated outputs and the needle tip position data are compared with 
the measured positions during experiments.
2) Preliminary Experiments in Tissue-Like Phantoms: 
Phantoms made of different gelatin/water ratios were first adopted to 
simulate the soft tissue, for it is easy to obtain and the properties are 
easy to control and replicate. The needle was driven into the phantom 
for 8 cm in the x-direction and 2 cm in the y-direction. The insertion 
speed was set to be 8, 4, and 2 mm/s, respectively. The lateral speed was 
chosen accordingly in order to keep the movements in x and y to start 
and stop simultaneously.
Fifth-order polynomials were chosen to represent the spring and damper 
coefficients. The initial coefficients were set to be [3 × 105 × ones
(6, 1); 2 × 106 × ones(6, 1); 1]. The initial covariance matrix was set to 
be [1016 × eye(13, 12)zeros(13, 1)]. The forgetting factor was selected to 
be 0.99. For comparison purpose, one segment was chosen first. Fig. 4 
shows one typical example of the simulated output versus the measured 
output. The corresponding measurement errors and the reconstructed 
depth-varying mean spring/damper coefficients using the estimated 
polynomial parameters are shown in Figs. 5–7.
To improve the tracking accuracy, two segments were chosen next. 
The same initial settings were used as in the one-segment estimation. 
The simulation errors of one-segment estimation and two-segment 
estimation are compared and shown in Fig. 8. We can see that the overall 
accuracy has improved when using two segments.
Figure 3. Experimental setup.
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3) Discussion: 
In this set of gelatin experiments, fifth-order polynomials were adopted 
for the spring and damper coefficients. Orders lower than fifth have 
shown larger estimation errors; while orders larger than fifth can 
give better accuracy, but no significant improvement. Dividing the 
whole insertion depth into more segments will improve the overall 
tracking accuracy, but not much improvement on the convergent 
rate, as can be detected in Fig. 8. The large estimation errors at the
beginning were caused by poor initial estimation and the large sensor 
noises due to the sudden oscillation of the sensors when the needle was
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accelerated to penetrate into the phantom; the relatively large estimation 
errors at the end were due to the erratic sensor output when the needle 
was decelerated to stop. The adjustment of the initial estimation has been 
found to be capable of decreasing the magnitude of the initial estimation 
error but cannot give much improvement on the convergent rate. This 
will be further investigated in later experiments.
The initial covariance matrix with magnitude larger than 1016 showed 
a better convergent rate, but not much improvement could be achieved 
especially when the magnitude is larger than 1018; less than 1016 would 
give a poor convergent rate with a decrease in overall accuracy.
The design of the online parameter estimator guarantees that the 
estimated coefficients will lead to minimum errors between the 
measured and estimated needle positions; this means that the process 
and measurement errors during the procedure may be incorporated 
into the parameter estimates, which is allowable since our goal is to 
achieve accurate needle position prediction, instead of precise parameter 
estimation. That is why even in the homogeneous gelatin phantom, the 
estimated spring/damper coefficients were found to be nonuniform in 
depth. In addition, the estimation is specific to the chosen trajectory. 
Thus, even in the same medium, it is highly possible that the estimated 
parameters will be different when choosing different trajectories.
More experiments will be carried out in the near future to further test the 
robustness of the steering model, as well as finding a method to improve 
the convergent rate.
III. Conclusion And Future Work
A needle steering model is proposed in this paper. Considering the 
tissue inhomogeneity, depth-varying mean parameters are adopted 
to calculate the tissue reaction effects. Local polynomials in finite 
segments are adopted to approximate the unknown depth-varying mean 
parameters. Based on this approach, an online parameter estimator has 
been designed using the modified least square method with a forgetting 
factor. Some preliminary experiments have been carried out to verify 
the steering model with the online parameter estimator. Results have 
shown its effectiveness. More experiments will be carried out in the 
near future to test the robustness of the steering model and improve the 
convergent rate. 
In the future, we will use the proposed needle steering model with an 
online parameter estimator to design an adaptive needle steering system 
that can steer the needle tip following some prescribed trajectory. The 
Aurora system and force sensor system can be adopted to measure 
the needle tip positions and needle base forces during the procedure.
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